Chimerix (CMRX) Tops Q1 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Chimerix (CMRX) Tops Q1 EPS by 3c

Chimerix (CHMX) PT Lifted to $50 at Brean Capital

May 11, 2015 12:37 PM EDT

Brean Capital analyst Jonathan Aschoff reiterated a Buy rating and boosted his price target on Chimerix (NASDAQ: CMRX) to $50.00 (from $45.00), saying Brinci has broad utility.

Aschoff commented, "The Phase 3 SUPPRESS trial with brincidofovir for the prevention of cytomegalovirus (CMV) in hematopoietic cell transplant patients is nearly 95% enrolled, and we expect it to be fully enrolled (n=450) in the summer of 2015 and read out pivotal... More